ACLS vs AMAT: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AMAT is the larger of the two ($242.13B market cap): the incumbent the market prices for continued execution (12.39x forward earnings, beta 1.67). ACLS is the smaller challenger ($2.80B), actually pricier on forward earnings (14.63x): more room to run, but more to prove. If you believe ACLS earns its premium (14.63x forward earnings, so the market expects more from it), ACLS fits. If you believe in paying less for profit, AMAT fits at 12.39x.

ACLS vs AMAT: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricACLSAMATWhat it tells you
Market cap$2.80B$242.13BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E14.6312.39Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E27.0024.18Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.891.67Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range14% of range17% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.529.27How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: AMAT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ACLS and AMAT affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACLS and AMAT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACLS and AMAT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Axcelis Technologies (ACLS) do?

Axcelis Technologies designs and sells ion implantation equipment for the semiconductor industry, along with the aftermarket service and spare parts (its CS&I business) that keep those tools running. Ion implantation is the process step that shoots charged atoms into silicon wafers to change their electrical properties, and it is essential to making almost every chip. The company's Purion product family serves a wide range of end markets, including power devices (notably silicon carbide chips used in electric vehicles and industrial systems), image sensors, general mature-node logic, and memory such as DRAM and high-bandwidth memory (HBM). Ion implantation makes up the large majority of revenue, so Axcelis is a fairly pure play on that one process step rather than a diversified equipment giant.

Full ACLS guide

What does Applied Materials (AMAT) do?

Applied Materials is the largest semiconductor equipment company in the world by revenue. The company manufactures the wafer fabrication equipment that semiconductor fabs use to deposit, etch, polish, and inspect silicon wafers. AMAT does not make lithography systems (ASML has that monopoly) but is essentially everywhere else in the fab equipment market.

Full AMAT guide

ACLS vs AMAT: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ACLS drivers: Memory recovery (DRAM and HBM); Power devices and silicon carbide.
  • AMAT drivers: Leading-edge logic and memory capex; Trailing-edge capacity expansion.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. For AMAT, semiconductor capex is cyclical.

ACLS or AMAT: which should you pick?

If the story you believe is ACLS's (Memory recovery (DRAM and HBM)), ACLS is the more direct way to own it; if it is AMAT's (Leading-edge logic and memory capex), AMAT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACLS and AMAT guides.

ACLS vs AMAT: the full fundamentals

ACLS. At ~$90.49 on November 20, 2026, Axcelis trades at about 27x trailing earnings, which are depressed, and ~15x forward estimates that assume EPS rises from ~$4.54 in 2026 to ~$6.20 in 2027. The stock fell ~28% over three months as gross margins slipped and the Veeco close was pushed out, even though revenue grew and bookings jumped. A net cash balance of roughly $400 million cushions the cycle. All figures are approximate and change with each quarter and the market.

AMAT. As of November 20, 2026, AMAT trades at about 24x trailing earnings and roughly 12x forward earnings (on fiscal 2028 estimates), with a price-to-sales ratio near 7x, down from 36x trailing in mid-October as the share price fell faster than estimates. The fiscal Q4 report beat on EPS ($4.16 vs ~$4.05) with revenue up about 53%, and consensus for fiscal Q1 2027 (expected around February 11, 2027) is EPS of ~$4.37 on ~$11.1 billion of revenue. The 36 analysts covering the stock rate it a strong buy on average, with a mean target near $558.

Headline figures (approximate, November 2026): ACLS shows revenue (ttm) ~$890 million (Q3 2026 up ~11.3% yoy), revenue (fy2025) ~$839 million, net income (ttm) ~$105 million (~12% margin), q3 2026 revenue ~$238 million (EPS ~$1.26 vs ~$1.11 est.); AMAT shows revenue (fy2026, ended oct. 25) ~$34.5 billion, revenue growth (latest quarter, yoy) ~53%, operating margin ~33%, net income (ttm) ~$10.1 billion.

The bottom line: ACLS vs AMAT

ACLS and AMAT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ACLS and AMAT exposure against your real portfolio. It is not an investment adviser.

Wondering how ACLS or AMAT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Axcelis Technologies

Ask Walnut's AI anything about ACLS and see how it fits what you own.

FAQ

What is the difference between ACLS and AMAT?

+

Axcelis Technologies designs and sells ion implantation equipment for the semiconductor industry, along with the aftermarket service and spare parts (its CS&I business) that keep those tools running. Applied Materials is the largest semiconductor equipment company in the world by revenue. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ACLS or AMAT the better stock?

+

Neither is universally better. AMAT is the larger incumbent; ACLS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ACLS or AMAT?

+

On forward P/E (as of November 2026), ACLS trades at 14.63x and AMAT at 12.39x, so AMAT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ACLS and AMAT?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ACLS vs AMAT?

+

ACLS: Axcelis is a small, highly cyclical company whose results swing with semiconductor capital-spending cycles it does not control, and its concentration in ion implantation means a slump in that step or in key end markets (like silicon carbide power chips) hits it hard, as the 2024 to 2025 revenue decline showed. A large share of demand comes from China (about 46% of third-quarter 2026 revenue), exposing the company to export controls, tariffs, and geopolitical tension that could restrict sales. The pending Veeco merger adds execution risk: its close has slipped to an expected end of the first quarter of 2027 while it awaits clearance in China, faces integration challenges, and could dilute or distract even if it closes. Margins are a fresh concern: second-quarter 2026 non-GAAP gross margin fell to ~42.7% from ~45.2% and non-GAAP operating margin to ~14.7% from ~17.7%, and third-quarter gross margin of ~41.2% missed the ~43% outlook, mainly on currency moves in the Korean won, so a beat on revenue and EPS still sent the shares lower. Customer concentration, competition from much larger equipment makers, and the general volatility of a roughly $2.8 billion market-cap chip-equipment stock, which swung between ~$73.60 and ~$193.78 over the past year and fell ~28% in the three months to November 20, 2026, round out the risks. AMAT: Semiconductor capex is cyclical. China exposure (where export controls have already cut some revenue) is the largest single near-term risk; further restrictions could expand. Valuation and sentiment have proven a risk of their own: the stock ran from a 52-week low of ~$216 to ~$740 and then fell about 36.5% over three months to $305 by November 20, 2026, with several brokers, most recently Daiwa, cutting price targets. Consensus still assumes fiscal 2027 EPS of ~$19.30 (up about 50%) on ~$48 billion of revenue and fiscal Q1 EPS of ~$4.37, so any sign that AI or memory capex is slowing would land against high expectations. Free cash flow of ~$2.5 billion trailing is well below net income of ~$10.1 billion, a gap worth watching as the company spends on capacity, inventory and R&D.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ACLS or AMAT; figures are approximate and dated (as of November 2026). Verify current data before investing.